Skip to main content

Table 3 Hazard ratios (95% CI) for mortality according to age at diagnosis and follow-up period, Collaborative Breast Cancer Studies

From: Pre-diagnosis oophorectomy, estrogen therapy and mortality in a cohort of women diagnosed with breast cancer

 

Person-years

All-cause mortality

Breast cancer mortality

Cardiovascular disease mortality

  

Deaths

HR (95% CI)a

Deaths

HR (95% CI)b

Deaths

HR (95% CI)b

Follow-up period:

       

5-year mortality

       

 Intact uterus and ovaries, never hormone use

15,462

537

1

331

1

59

1

 TAHBSOc

6,165

170

0.93 (0.78, 1.10)

103

0.93 (0.74, 1.16)

19

0.94 (0.55, 1.58)

  TAHBSO, Never used hormones

1,857

64

0.91 (0.70, 1.19)

31

0.79 (0.54, 1.16)

10

1.14 (0.58, 2.24)

  TAHBSO, Used unopposed estrogens

3,596

90

0.93 (0.75, 1.17)

61

1.03 (0.77, 1.36)

7

0.70 (0.32, 1.55)

Mortality among 5-year survivors

       

 Intact uterus and ovaries, never hormone use

27,759

1,340

1

330

1

267

1

 TAHBSOc

11,384

387

0.80 (0.72, 0.90)

95

0.81 (0.64, 1.02)

75

0.82 (0.63, 1.06)

  TAHBSO, Never used hormones

3,541

177

0.82 (0.78, 1.07)

28

0.69 (0.46, 1.01)

48

1.19 (0.87, 1.63)

  TAHBSO, Used unopposed estrogens

6,649

180

0.72 (0.62, 0.85)

59

0.92 (0.69, 1.23)

24

0.53 (0.35, 0.81)

Age at diagnosis:

       

50-64 years d

       

 Intact uterus and ovaries, never hormone use

20,968

593

1

326

1

60

1

 TAHBSOc

9,559

189

0.78 (0.66, 0.91)

103

0.78 (0.62, 0.98)

15

0.61 (0.34, 1.09)

  TAHBSO, Never used hormones

1,890

47

0.80 (0.59, 1.08)

22

0.68 (0.43, 1.07)

6

0.97 (0.42, 2.24)

  TAHBSO, Used unopposed estrogens

6,391

115

0.75 (0.61, 0.92)

68

0.85 (0.65, 1.12)

5

0.32 (0.13, 0.80)

≥ 65 years

       

 Intact uterus and ovaries, never hormone use

22,253

1,284

1

335

1

296

1

 TAHBSOc

7,990

368

0.86 (0.77, 0.97)

95

0.95 (0.75, 1.20)

79

0.90 (0.69, 1.15)

  TAHBSO, Never used hormones

3,507

194

0.95 (0.82, 1.11)

37

0.76 (0.54, 1.08)

52

1.21 (0.89, 1.64)

  TAHBSO, Used unopposed estrogens

3,854

155

0.80 (0.67, 0.94)

52

1.15 (0.85, 1.54)

26

0.65 (0.43, 0.98)

  1. aHazard ratios adjusted for age, study enrollment years, state, body mass index, cigarette smoking, family history of breast cancer, and stage at diagnosis; bcumulative incidence subhazard ratios adjusted for age, study enrollment years, state, body mass index, cigarette smoking, family history of breast cancer, and stage at diagnosis; cTAHBSO, total abdominal hysterectomy with bilateral salpingo-oophorectomy; ddue to the low number of cardiovascular disease mortality events among women ages 50 to 64 at diagnosis, full multivariate adjustment was not performed. CVD mortality cumulative incidence subhazard ratios are adjusted for age, study enrollment years, and stage at diagnosis.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us